M1774 (tuvusertib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for M1774 (tuvusertib), covering 2026-04-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial [Phase 2]